Ursula Scholz, MD

Articles by Ursula Scholz, MD

UFT/Leucovorin Combined With Paclitaxel for Anthracycline-Pretreated Advanced Breast Cancer

ByUrsula Scholz, MD,Hans-Joachim Lück, MD,Ulrich Canzler, MD,Dagmar Robner, MD,Henning Kühnle, MD

October 1st 2000

Taxanes are the most active drugs in the treatment of metastatic breast and ovarian cancer. Weekly therapy with paclitaxel produces notable activity, with remarkably low toxicity.

UFT/Oral Calcium Folinate Plus Weekly Paclitaxel for Metastatic Breast Cancer

ByHans-Joachim Lück, MD,Ursula Scholz, MD,H. Kühnle, MD,J. Dethling, MD

July 1st 1999

Paclitaxel (Taxol) is one of the most active drugs in the treatment of ovarian and breast cancers. Combination therapy with paclitaxel and 5-fluorouracil (5-FU) exhibits high activity in anthracycline-pretreated breast cancer,

Latest Updated Articles

UFT/Leucovorin Combined With Paclitaxel for Anthracycline-Pretreated Advanced Breast Cancer
October 1st 2000
UFT/Oral Calcium Folinate Plus Weekly Paclitaxel for Metastatic Breast Cancer
July 1st 1999

Trending on CancerNetwork

FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy

Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer

FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer

TIP125 ReDiscover-2, a Phase 3 Study of Zovegalisib (RLY-2608) + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-Mutant HR+/ HER2- Breast Cancer Following Recurrence or Progression on or After Treatment With a CDK4/6 Inhibitor (Trial in Progress)